

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE THIRD QUARTER OF 2023

This announcement is made by Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the third quarter of 2023, the Company has recorded a total product revenue over RMB1.6 billion, representing a robust year-over-year growth of over 45% and a significant quarter-on-quarter growth, with continuously improving operational productivity and efficiency.

During the third quarter of 2023, the Company continued to fully leverage its diversified product portfolio, broad national reimbursement drug list (NRDL) coverage, comprehensive market channels, adequate clinical evidence, and healthy commercial operation model to meet the clear market demand for innovative medicines with high quality and clinical value. TYVYT[®] (sintilimab injection) continued its strong sales performance and solid market leading position, and the other products also achieved significant volume ramp-up during the quarter. Meanwhile, revenue contribution from new products kept increasing, which further support the Company's sustainable growth.

In addition, the Company's tenth product in its commercial portfolio and also the first product in the cardiovascular and metabolism (CVM) area, SINTBILO[®] (tafolecimab injection) was approved in August 2023. The Company is committed to building a compelling product portfolio and brand franchise in both oncology and non-oncology areas to support our long-term growth.

The Company has built a robust pipeline of over 30 valuable assets in the fields of cancer, metabolic, autoimmune diseases, ophthalmology diseases and other major therapeutic areas. As of now, the Company has ten approved products, including: TYVYT[®] (sintilimab injection), BYVASDA[®] (bevacizumab injection), SULINNO[®] (adalimumab injection), HALPRYZA[®] (rituximab injection), PEMAZYRE[®] (pemigatinib), olverembatinib, Cyramza[®] (ramucirumab), Retsevmo[®] (selpercatinib), FUCASO[®] (Equecabtagene Autoleucel) and SINTBILO[®] (tafolecimab injection). Besides, 7 assets are in Phase III or pivotal clinical trials, and approximately 20 additional molecules are in clinical studies. The Company believes that its robust innovative pipeline with great market potential will firmly support the sustainable growth of the Company under the committed strategy of global innovation.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
November 2, 2023

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.